Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

• Status: Completed
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

We aimed to assess changes in pancreatic fat content in people with diabetes on dapagliflozin (SGLT2 inhibitor) and beta cell function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Age ≥ 18 years,

2. Hba1c 7-11%,

3. Renal function (MDRD) > 30 ml/min, on glucose-lowering therapy {metformin, sulfonylureas, glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, or basal insulin} at a stable dose for at least 3 months.

Exclusion Criteria:

1. Uncontrolled hyperglycemia at screening (fasting blood glucose FBG ≥ 240 mg/dL).

2. Diabetes other than type 2 diabetes

3. Age younger than 18 years.

4. Pregnant patients or lactating.

5. Patients who refuse to give consent to be enrolled in the study.

6. Any contraindication to magnetic resonance imaging.

7. More than 5% total body weight loss within the last month.

8. Patients with moderate or severe renal impairment

9. Any contraindication to SGLT2i

10. Prior SGLT2i within the past 3 months